Ownership and insider activity for Can-Fite BioPharma Ltd. (CANF): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19.
Price
| Price | $2.24 |
| Market Cap | $3M |
| Exchange | AMEX |
| Country | IL |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.1M | $3.5M | $3.6M | $2.7M | $8.3M | $4.4M | $3.0M | $4.3M | $4.8M | $5.5M |
| Short-term Investments | 0 | 0 | $273000 | $64000 | $75000 | $14.7M | $5.0M | $4.6M | $3.1M | $3.0M |
| Receivables | $21837 | 0 | 0 | $637000 | $18000 | $48000 | $47000 | 0 | 0 | $73998 |
| Inventory | 0 | -$3.3M | -$4.0M | -$715000 | 0 | -$48000 | -$39000 | 0 | 0 | 0 |
| Total Current Assets | $10.1M | $6.9M | $7.9M | $7.1M | $9.4M | $20.1M | $9.2M | $9.9M | $9.0M | $9.4M |
| Property, Plant & Equipment | $53293 | $46035 | $47000 | $118000 | $123000 | $185000 | $126000 | $81000 | $138000 | $73998 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $10.2M | $7.8M | $8.0M | $8.2M | $9.5M | $20.3M | $9.3M | $10.0M | $9.1M | $9.5M |
| Accounts Payable | $1.2M | $427000 | $1.1M | $2.2M | $561000 | $954000 | $896000 | $427000 | $618000 | $1.2M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $2.5M | $1.8M | $3.1M | $3.3M | $1.3M | $2.7M | $2.5M | $2.0M | $2.1M | $2.7M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $6.3M | $4.8M | $4.9M | $5.7M | $3.4M | $5.9M | $4.8M | $3.7M | $3.7M | $3.9M |
| Retained Earnings | -$91.0M | -$105.7M | -$100.6M | -$110.3M | -$125.5M | -$140.7M | -$150.8M | -$158.5M | -$166.4M | -$176.2M |
| Total Equity | $3.9M | $3.1M | $3.0M | $2.4M | $6.1M | $14.4M | $4.5M | $6.2M | $5.4M | $5.6M |
| Total Debt | 0 | 0 | 0 | $75000 | $67000 | $124000 | $62000 | $40000 | $104000 | $70998 |
| Net Debt | -$8.1M | -$3.5M | -$3.9M | -$2.7M | -$8.3M | -$19.0M | -$7.9M | -$8.9M | -$7.8M | -$8.5M |
| Working Capital | $7.6M | $5.1M | $4.8M | $3.9M | $8.1M | $17.3M | $6.7M | $7.9M | $6.9M | $6.7M |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 3.46 |
Profitability
| Return on Equity | -201.06% |
| Return on Invested Capital | -145.49% |
| Return on Assets | -103.30% |
| Gross Margin | 100.00% |
| Operating Margin | -2456.79% |
| Net Margin | -2426.67% |
Related companies: BDRX · CLDI · CMND · CNSP · GRI · JAGX · KZIA
Explore sector: Healthcare · Biotechnology
More sections of CANF: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks